Merck KGaA says it has reached an R&D 'critical mass'

Merck KGaA, long troubled by pipeline setbacks, said it's back on track thanks to some high-profile partnerships and a particular focus on immuno-oncology. Speaking to Reuters, Luciano Rossetti, head of R&D at the company's Serono division, said Merck KGaA has "more than enough critical mass in oncology" after signing deals with Pfizer ($PFE) and Threshold Pharmaceuticals ($THLD), part of the German drugmaker's plans to bolster its pipeline as the top-selling Rebif loses ground to new competitors. "We see people who want to work with us in R&D," Rossetti said. "This wasn't true a few years ago." More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.